DYNAMIC FEATURES OF THE HUMORAL IMMUNITY IN PATIENTS WITH ACUTE CORONARY SYNDROME DEPENDING ON THE CONTENT OF B-LYMPHOCYTES WITH THE CD3 - CD19 + CD5 + PHENOTYPE, WHO HAVE AND HAVE NOT HAD COVID-19

The purpose of the work was to study the dynamic features of the humoral immunity in patients with acute coronary syndrome depending on the content of B-lymphocytes with the CD3 - CD19 + CD5 + phenotype, who had and did not have COVID-19. Methods. We analyzed data on humoral immunity in men aged 40 to 65 years with acute coronary syndrome, who had and did not have COVID-19, depending on the content of B-lymphocytes with the CD3 - CD19 + CD5 + phenotype. All patients underwent coronary angiography with further stenting of the coronary arteries. The values of lymphocytes with the CD45+CD3-CD19+ phenotype and the presence or absence of COVID-19 previously were taken into account. Using the flow cytometry method, 2 groups were gated using the pan-leukocyte marker CD45+: the subgroup of B-lymphocytes CD3 - CD19 + CD5 + and the subgroup of B-lymphocytes CD3-CD19+CD5-, B-lymphocytes (CD45+CD3- CD19+). Levels of total IgA, IgG, IgM, C1-inhibitor, C3a and C5a complement components by enzyme immunoassay. Results. Of those with decreased CD3 - CD19 + CD5 + B cells with a history of COVID-19, ST-segment elevation AMI (STEMI) was observed in 9 (40.91%) patients, non-ST elevation AMI (NSTEMI) - in 2 ( 9.09%), unstable angina (UA) - in 11 (50%). This was the most severe in comparison with other groups of patients. The lowest number of B-lymphocytes (CD45+CD3-CD19+) in relative terms (8.90±1.16%) was lower in individuals with COVD-19 and having reduced B-cells with the CD3-CD19+CD5+ phenotype, which is significant (p<0.0001) differed from groups with normal (14.51±0.88%) and elevated CD3-CD19+CD5+ cells (15.13±2.09%), who had COVID-19, and from individuals with normal (16.66±2.07%) and elevated CD3 - CD3-CD19+CD5+ cells (22.4±3.95), who did not have COVID-19. Significantly (p<0.05) in relative dynamics, B-lymphocytes (CD45+CD3– CD19+) increased in patients with initially low B-cells with the phenotype CD3-CD19+CD5+, who did not have COVID-19 (from 10.18 ±3.81% to 19.1±7.56%), and decreased relatively (p<0.01) in patients with normal CD3-CD19+CD5+ cells who had COVID-19. In absolute numbers, there was a dynamic increase in this indicator in patients with reduced CD3-CD19+CD5+ cells who had COVID-19: from 128.05±13.99 to 194.82±18.77, 10 6 cells/l (p< 0.001) and those who did not have COVID-19: from 124±54.48 to 283.5±54.47, 10 6 cells/l (p<0.05). Conclusions. After coronary artery stenting, B lymphocytes (CD3-CD19+CD5+) significantly increased in the group of people with COVID-19, with initially low levels of these cells (p<0.01) and normal cells (p<0.05). In individuals who had COVID-19 and did not have this disease, with initially decreased CD3-CD19+CD5+ cells, B-lymphocytes (CD45) increased significantly (p<0.001 and p<0.05, respectively) over time (p<0.05 +CD3- CD19+), B-lymphocytes (CD3-CD19+CD5-. In the group of patients who recovered from COVID-19 with normal CD3-CD19+CD5+ cells, the relative number of B-lymphocytes decreased over time (p<0.01) ( CD45+CD3- CD19+) and CD3-CD19+CD5- cells. In persons who had previously suffered from COVID-19, with increased CD3-CD19+CD5+ cells, the number of B-lymphocytes (CD45+) significantly (p<0.05) decreased over time CD3- CD19+), in those who did not have COVID-19 with high above-mentioned cells, immunoglobulin A significantly (p < 0.05) increased. The most severe clinically was the group of people with low CD3 - CD19 + CD5 + B cells and COVID-19 in the anamnesis.